Lisa Conroy

Lisa Conroy is the Director of Communications at Antidote. She is a seasoned health communications strategist dedicated to understanding the reasons people make the health choices they do, and determining what that means in terms of how scientific data should be communicated. Prior to her role at Antidote, Lisa ran the TEDMED Great Challenges program, a public health initiative funded by RWJF. She also has experience working in pharmaceutical public relations in the areas of respiratory diseases, oncology, and HIV. Lisa holds an MPH from Columbia and a BA in English and International Studies from Northwestern.

[Webinar] We Asked 4,000 Patients about Clinical Trials: Here's What Matters Most

It’s no secret that recruiting patients for clinical trials can be a difficult endeavor. And, even when a trial meets its quotas and timelines, many still do not reflect real-world populations. So how can we better engage patients from all walks of life in medical research? 

Continue reading

Learn About Precision Recruitment at SCRS 2019

We’re gearing up to head to Florida later this week for the SCRS Site Solutions Summit, the annual meeting that brings sites, sponsors, CROs, and regulators together to discuss the current state of clinical research and where we go from here. We’re looking forward to meeting some of the brightest in the business, and sharing best practices that can drive success for all. 

Continue reading

Leadership Profile: An Interview with Antidote CFO Keith Lovell

Keith Lovell joined Antidote as CFO in September 2015, bringing more than 25 years of financial and commercial experience at companies ranging from major blue chip organizations to startups. Prior to Antidote, he was employee number 30 at Shazam, and helped build it up to a billion dollar valuation. 

Continue reading

Antidote Named Scrip Award Finalist for “Best Technological Development in Clinical Trials”

The Scrip Awards are where the industry’s best and brightest are recognized for excellence across the drug development spectrum. That’s why we’re absolutely honored to announce that Antidote has been named a Scrip Awards finalist in the category of “Best Technological Development in Clinical Trials.” We’ve been a finalist in this category before, and are thrilled that the evolution of our ...

Continue reading

Putting patients at the center starts with trust

A few years ago, we wrote a blog series for ACRP in which we focused on patient centricity in clinical trial design, recruitment, and execution. Over the next few months, we’ll be taking a second look at those blog posts, sharing updated versions on our own blog. Here’s an update to the second in that series. 

Continue reading

A Year in Review: An Interview with Antidote CEO, Laurent Schockmel

It’s been one year since Laurent Schockmel took the helm at Antidote. We sat down with Laurent to talk about his journey from scientist to CEO and hear his reflections on his first year at Antidote. Here’s what he had to say:

Continue reading

Why quality matters more than quantity in clinical trial patient recruitment

Today, nearly 60 million patients are needed for currently recruiting clinical trials. And in fact, 80% of trials will be delayed or closed due to difficulty finding patients to take part. 

Continue reading

Webinar: "What I've Learned in 20 Years of Patient Recruitment"

As medications become more targeted and sophisticated, the growing complexity of clinical trial protocols is making it more difficult than ever to find the perfect patients for your trials. That’s why a thoughtful and strategic patient recruitment strategy is key.  

Continue reading

How We Delivered 300% of Our Clinical Trial Recruitment Goal [Case Study]

While approximately 15 to 20 percent of people 65+ have Mild Cognitive Impairment (MCI), it can be difficult to identify, and difficult to determine if it is related to Alzheimer’s disease. MCI does not always lead to dementia, but people with MCI are four times more likely to develop Alzheimer’s disease and other forms of dementia than those without it — so it’s important to treat this condition ...

Continue reading

Patient Centricity in Clinical Trials: Progress — and Miles to Go

A few years ago, we wrote a blog series for ACRP in which we focused on patient centricity in clinical trial design, recruitment, and execution. Over the next few months, we’ll be taking a second look at those blog posts, sharing updated versions on our own blog. Here’s an update to the first in that series. 

Continue reading

Get our latest posts in your inbox.